Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Abstract Background: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acqui red pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in ho spitalized CAP patients. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores: Tanaseanu, Cristina, Milutinovic, Slobodan, Calistru, Petre I., Strausz, Janos, Zolubas, Marius, Chernyak, Valeriy, Dartois, Nathalie, Castaing, Nathalie, Gandjini, Hassan, Cooper, C. Angel, Gudiol i Munté, Francesc
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/54556
Acceso en línea:https://hdl.handle.net/2445/54556
Access Level:acceso abierto
Palabra clave:Pneumònia adquirida a la comunitat
Antibiòtics
Assaigs clínics de medicaments
Community-acquired pneumonia
Antibiotics
Drug testing
id ES_0b448d3e2e4a8b60cc077b33478439f2
oai_identifier_str oai:recercat.cat:2445/54556
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.Tanaseanu, CristinaMilutinovic, SlobodanCalistru, Petre I.Strausz, JanosZolubas, MariusChernyak, ValeriyDartois, NathalieCastaing, NathalieGandjini, HassanCooper, C. AngelGudiol i Munté, FrancescPneumònia adquirida a la comunitatAntibiòticsAssaigs clínics de medicamentsCommunity-acquired pneumoniaAntibioticsDrug testingAbstract Background: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acqui red pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in ho spitalized CAP patients. The aim of the present study was to compare the efficacy and safety of intravenous (IV) tigecycline with IV levofloxacin in hospitalized adults with CAP. Methods: In this prospective, double-blin d, non-inferiority phase 3 trial, eligible patients with a clinical diagnosis of CAP supported by radiographic evidence were stratified by Fine Pneumonia Severity Index and randomized to tigecycline or levofloxacin for 7-14 days of therapy. Co-primary efficacy endpoints were clinical response in the clinically evaluable (CE) and clinical modified intent- to-treat (c-mITT) populations at te st-of-cure (Day 10-21 post-therapy). Results: Of the 428 patients who received at least on e dose of study drug, 79% had CAP of mild-moderate severity according to their Fine score. Clinical cure rates for the CE population were 88.9% for tigecycline and 85.3% for levofloxac in. Corresponding c-mITT population rates were 83.7% and 81.5%, respectively. Eradication rates for Streptococcus pneumoniae were 92% for tigecycline and 89% for levofloxac in. Nausea, vomiting, and diarrhoea were the most frequently reported adverse events. Rates of premature disc continuation of study drug or study withdrawal because of any adverse event were similar for both study drugs. Conclusion: These findings suggest that IV tigecycline is non-inferior to IV levofloxacin and is generally well-tolerated in the treatment of hospitalized adults with CAP.BioMed Central2014201420092014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion11 p.application/pdfhttps://hdl.handle.net/2445/54556Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: http://dx.doi.org/10.1186/1471-2466-9-44BMC Pulmonary Medicine, 2009, vol. 9, p. 44http://dx.doi.org/10.1186/1471-2466-9-44cc-by (c) Tanaseanu, C. et al., 2009http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/545562026-05-29T05:05:01Z
dc.title.none.fl_str_mv Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
title Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
spellingShingle Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Tanaseanu, Cristina
Pneumònia adquirida a la comunitat
Antibiòtics
Assaigs clínics de medicaments
Community-acquired pneumonia
Antibiotics
Drug testing
title_short Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
title_full Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
title_fullStr Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
title_full_unstemmed Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
title_sort Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
dc.creator.none.fl_str_mv Tanaseanu, Cristina
Milutinovic, Slobodan
Calistru, Petre I.
Strausz, Janos
Zolubas, Marius
Chernyak, Valeriy
Dartois, Nathalie
Castaing, Nathalie
Gandjini, Hassan
Cooper, C. Angel
Gudiol i Munté, Francesc
author Tanaseanu, Cristina
author_facet Tanaseanu, Cristina
Milutinovic, Slobodan
Calistru, Petre I.
Strausz, Janos
Zolubas, Marius
Chernyak, Valeriy
Dartois, Nathalie
Castaing, Nathalie
Gandjini, Hassan
Cooper, C. Angel
Gudiol i Munté, Francesc
author_role author
author2 Milutinovic, Slobodan
Calistru, Petre I.
Strausz, Janos
Zolubas, Marius
Chernyak, Valeriy
Dartois, Nathalie
Castaing, Nathalie
Gandjini, Hassan
Cooper, C. Angel
Gudiol i Munté, Francesc
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Pneumònia adquirida a la comunitat
Antibiòtics
Assaigs clínics de medicaments
Community-acquired pneumonia
Antibiotics
Drug testing
topic Pneumònia adquirida a la comunitat
Antibiòtics
Assaigs clínics de medicaments
Community-acquired pneumonia
Antibiotics
Drug testing
description Abstract Background: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acqui red pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in ho spitalized CAP patients. The aim of the present study was to compare the efficacy and safety of intravenous (IV) tigecycline with IV levofloxacin in hospitalized adults with CAP. Methods: In this prospective, double-blin d, non-inferiority phase 3 trial, eligible patients with a clinical diagnosis of CAP supported by radiographic evidence were stratified by Fine Pneumonia Severity Index and randomized to tigecycline or levofloxacin for 7-14 days of therapy. Co-primary efficacy endpoints were clinical response in the clinically evaluable (CE) and clinical modified intent- to-treat (c-mITT) populations at te st-of-cure (Day 10-21 post-therapy). Results: Of the 428 patients who received at least on e dose of study drug, 79% had CAP of mild-moderate severity according to their Fine score. Clinical cure rates for the CE population were 88.9% for tigecycline and 85.3% for levofloxac in. Corresponding c-mITT population rates were 83.7% and 81.5%, respectively. Eradication rates for Streptococcus pneumoniae were 92% for tigecycline and 89% for levofloxac in. Nausea, vomiting, and diarrhoea were the most frequently reported adverse events. Rates of premature disc continuation of study drug or study withdrawal because of any adverse event were similar for both study drugs. Conclusion: These findings suggest that IV tigecycline is non-inferior to IV levofloxacin and is generally well-tolerated in the treatment of hospitalized adults with CAP.
publishDate 2009
dc.date.none.fl_str_mv 2009
2014
2014
2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/54556
url https://hdl.handle.net/2445/54556
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/10.1186/1471-2466-9-44
BMC Pulmonary Medicine, 2009, vol. 9, p. 44
http://dx.doi.org/10.1186/1471-2466-9-44
dc.rights.none.fl_str_mv cc-by (c) Tanaseanu, C. et al., 2009
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Tanaseanu, C. et al., 2009
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 11 p.
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403210888773633
score 15,811543

Similares en LA Referencia